Xtl Biopharmaceuticals (XTLB) Liabilities from Discontinued Operations (2014 - 2024)
Xtl Biopharmaceuticals (XTLB) posted quarterly Liabilities from Discontinued Operations of 1867000.0 for Q4 2024, up 515.81% on a QoQ basis from 449000.0 in Q4 2015.
Xtl Biopharmaceuticals (XTLB) Liabilities from Discontinued Operations (2014 - 2024) Analysis & Trends
Xtl Biopharmaceuticals (XTLB) has reported Liabilities from Discontinued Operations for 3 consecutive years, with 1867000.0 the latest figure, recorded in Q4 2024.
- Quarterly Liabilities from Discontinued Operations changed N/A year-over-year to 1867000.0 in Q4 2024, while the trailing twelve-month figure through Dec 2024 was 1867000.0 (changed N/A YoY) and the FY2024 annual result came in at 1867000.0, changed N/A from the prior year.
- Liabilities from Discontinued Operations rose to 1867000.0 in Q4 2024 per XTLB's latest filing, from 449000.0 in the prior quarter.
- Over the last five years, Liabilities from Discontinued Operations for XTLB reached as high as 1867000.0 in Q4 2024 and fell as low as 1867000.0 in Q4 2024.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - |
| 10 | Xtl Biopharmaceuticals | 2.60 Bn | 2.60 Bn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2024 | 1.87 Mn |
| Dec 31, 2024 | 1.87 Mn |
| Dec 31, 2015 | -449,000.00 |
| Dec 31, 2015 | -449,000.00 |
| Dec 31, 2014 | 450,000.00 |
| Dec 31, 2014 | 450,000.00 |